secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2026-05-27T10:37:49+00:00
Accession:  0001104659-26-066572
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee reports positive Phase 2 Part B data for zumilokibart; mid-dose 65.9% EASI-75 vs 23.4% placebo
--------------------------------------------------------------------------------

- Primary endpoint met: 65.9% mid-dose EASI-75 (p<0.001 vs placebo 23.4%) at 16 weeks.
- Key secondary endpoints: IGA 0/1 46.0%, EASI-90 47.4%, I-NRS≥4 50.5% (all p<0.001).
- Safety consistent with class; conjunctivitis rate for mid-dose 10.6% vs 15.1% low and 20.7% high.
- Plans to initiate Phase 3 ADventure trials in 2H 2026; also Phase 2b asthma and Phase 2a EoE trials.
- Blackstone Life Sciences strategic financing collaboration announced to fund through commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465926066572/0001104659-26-066572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465926066572/tm2615568d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-066572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer